Back

Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase

19 May 2025 (15:00 - 15:45)
Organised by: Logo
Congress Presentation Part of: Advances in heart failure therapeutics Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Mark C Petrie

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Refining definitions of severe and advanced heart failure: insight from the swedish heart failure registry to optimize trial design and improve referral to advanced therapies
Doctor F. Guidetti (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Association between neutrophil-to-lymphocyte ratio, exercise capacity and outcomes in patients with heart failure and reduced ejection fraction
Doctor E. Rodenas Alesina (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial
Doctor P. Tolomeo (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on patients' needs and perceptions
Ms R. Monroe (Charlotte, US)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in heart failure therapeutics

The Event

Event poster

Heart Failure 2025

19 May 2025 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF
thumbnail
Congress Presentation
Real-world use and effectiveness of patiromer among patients with heart failure at high risk of hyperkalaemia: insights from the CARE-HK in HF registry
thumbnail
Congress Session
Late breaking clinical trials: further analyses and baseline characteristics

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources